Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

61 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
ERBB receptors and cancer: the complexity of targeted inhibitors.
Hynes NE, Lane HA. Hynes NE, et al. Nat Rev Cancer. 2005 May;5(5):341-54. doi: 10.1038/nrc1609. Nat Rev Cancer. 2005. PMID: 15864276 Review.
Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.
O'Reilly T, McSheehy PM, Wartmann M, Lassota P, Brandt R, Lane HA. O'Reilly T, et al. Among authors: lane ha. Anticancer Drugs. 2011 Jan;22(1):58-78. doi: 10.1097/CAD.0b013e3283400a20. Anticancer Drugs. 2011. PMID: 20890178
The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.
Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA, Thomas G. Beuvink I, et al. Cell. 2005 Mar 25;120(6):747-59. doi: 10.1016/j.cell.2004.12.040. Cell. 2005. PMID: 15797377
Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.
O'Reilly T, Lane HA, Wood JM, Schnell C, Littlewood-Evans A, Brueggen J, McSheehy PM. O'Reilly T, et al. Cancer Chemother Pharmacol. 2011 Jan;67(1):193-200. doi: 10.1007/s00280-010-1307-z. Epub 2010 May 30. Cancer Chemother Pharmacol. 2011. PMID: 20512579
Optimal targeting of the mTORC1 kinase in human cancer.
Lane HA, Breuleux M. Lane HA, et al. Curr Opin Cell Biol. 2009 Apr;21(2):219-29. doi: 10.1016/ Epub 2009 Feb 21. Curr Opin Cell Biol. 2009. PMID: 19233631 Review.
The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer.
Boulay A, Breuleux M, Stephan C, Fux C, Brisken C, Fiche M, Wartmann M, Stumm M, Lane HA, Hynes NE. Boulay A, et al. Cancer Res. 2008 May 15;68(10):3743-51. doi: 10.1158/0008-5472.CAN-07-5100. Cancer Res. 2008. PMID: 18483257
Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.
Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, Kwiatkowski D, Lane HA. Breuleux M, et al. Mol Cancer Ther. 2009 Apr;8(4):742-53. doi: 10.1158/1535-7163.MCT-08-0668. Mol Cancer Ther. 2009. PMID: 19372546 Free PMC article.
AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.
Marinov M, Ziogas A, Pardo OE, Tan LT, Dhillon T, Mauri FA, Lane HA, Lemoine NR, Zangemeister-Wittke U, Seckl MJ, Arcaro A. Marinov M, et al. Clin Cancer Res. 2009 Feb 15;15(4):1277-87. doi: 10.1158/1078-0432.CCR-08-2166. Clin Cancer Res. 2009. PMID: 19228731
mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T. Lane HA, et al. Clin Cancer Res. 2009 Mar 1;15(5):1612-22. doi: 10.1158/1078-0432.CCR-08-2057. Epub 2009 Feb 17. Clin Cancer Res. 2009. PMID: 19223496
The mammalian target of rapamycin kinase and tumor growth inhibition.
Boulay A, Lane HA. Boulay A, et al. Recent Results Cancer Res. 2007;172:99-124. doi: 10.1007/978-3-540-31209-3_7. Recent Results Cancer Res. 2007. PMID: 17607938 Review. No abstract available.
61 results
Jump to page